What is the optimal management for a 42‑year‑old man with severe calcific bicuspid aortic stenosis, moderate aortic regurgitation, concentric left‑ventricular hypertrophy, preserved ejection fraction, and a dilated ascending aorta (48 mm) presenting with dyspnea?

Surgical Intervention is Indicated Now

This 42-year-old man with severe calcific bicuspid aortic stenosis presenting with dyspnea requires urgent surgical aortic valve replacement (AVR) combined with ascending aortic replacement. The presence of symptoms (dyspnea) with severe AS is an absolute Class I indication for intervention, and the ascending aortic diameter of 48 mm in a patient with bicuspid aortic valve (BAV) meets the threshold for concomitant aortic surgery 1, 2, 3.

Primary Indication: Symptomatic Severe Aortic Stenosis

The patient's dyspnea represents a valve-related symptom in the context of severe AS (peak velocity 4.82 m/s, mean gradient 82 mmHg, AVA 0.92 cm²). All major guidelines unanimously recommend AVR for symptomatic severe AS regardless of left ventricular function 2, 4, 5. This is a Class I, Level B recommendation with the strongest evidence base in valvular heart disease.

The preserved ejection fraction (55%) is favorable for surgical outcomes, but does not change the indication—symptoms alone mandate intervention. The concentric LVH reflects appropriate compensatory response to chronic pressure overload.

Concomitant Ascending Aortic Replacement: Mandatory

The ascending aortic diameter of 48 mm in a BAV patient undergoing AVR creates a Class I indication for concomitant aortic replacement 1, 2, 3, 6:

• The 2024 ESC guidelines explicitly state that surgery of the ascending aorta is indicated when the aortic root or ascending aortic diameter is ≥45 mm and surgical AVR is scheduled 1
• The 2020 ACC/AHA guidelines recommend ascending aortic replacement when diameter exceeds 4.5 cm at the time of AVR in BAV patients 3
• The AATS consensus guidelines on BAV-related aortopathy support the 4.5 cm threshold for concomitant aortic surgery 6

Why 45 mm Matters in BAV

The lower threshold (45 mm vs. 50-55 mm for isolated aortopathy) is justified because:

1. Surgical efficiency: The aorta is already accessed for AVR, adding minimal additional risk
2. Thin aortic wall: At 45+ mm, the BAV aortic wall becomes effaced and technically challenging, risking catastrophic tears during valve surgery 6
3. Progressive dilation risk: The aorta continues to dilate post-AVR in BAV patients, with 10% requiring subsequent aortic surgery 3
4. Low dissection risk post-AVR: While acute dissection risk is low, elective concomitant repair prevents future reoperations 6

Surgical Approach

Valve Selection

At age 42, a mechanical aortic valve is strongly recommended 5. The 2020 ACC/AHA guidelines recommend mechanical valves for patients <50 years, and the ESC/EACTS guidelines favor mechanical over bioprosthetic in the 50-60 age range 5. This avoids structural valve deterioration requiring reoperation in 10-15 years with a bioprosthetic valve.

The patient must accept lifelong warfarin anticoagulation (target INR 2.0-3.0 for mechanical aortic valve). Counsel regarding bleeding risk, dietary vitamin K consistency, and pregnancy considerations if applicable.

Extent of Aortic Surgery

Replace the ascending aorta from sinotubular junction to proximal arch 1, 7, 6. The aortic root (annulus 28 mm, sinuses not severely dilated based on STJ 40 mm) does not require replacement—perform isolated AVR with supracoronary ascending aortic replacement using a Dacron tube graft.

Root replacement (Bentall procedure) would only be indicated if:

• Aortic root diameter exceeded 45 mm
• Severe aortic regurgitation required root repair
• Intraoperative findings showed root pathology

Valve-Sparing Surgery: Not Appropriate Here

The densely calcified bicuspid valve with severe stenosis is not amenable to repair 7, 6. Valve-sparing root operations (David or Yacoub procedures) are reserved for BAV patients with:

• Pure or predominant aortic regurgitation
• Pliable, non-calcified leaflets
• Root aneurysm requiring replacement

Management of Moderate Aortic Regurgitation

The moderate eccentric AR does not change surgical planning. When severe AS and moderate AR coexist, the stenosis determines timing and the AR is addressed by valve replacement 4. The AR likely results from leaflet calcification and will be eliminated by AVR.

Preoperative Optimization

Immediate Actions

1. Avoid vasodilators: ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers can cause profound hypotension in severe AS 2, 8. If hypertension requires treatment, use beta-blockers cautiously.

2. Diuretics for symptom relief: Gentle diuresis may improve dyspnea, but avoid aggressive volume depletion that reduces preload and cardiac output.

3. Expedited surgical referral: Symptomatic severe AS carries 50% 2-year mortality without intervention 2. Schedule surgery within 2-4 weeks, not months.

Preoperative Imaging

The echocardiogram provides adequate information for surgical planning. CT angiography of the entire thoracic aorta is indicated to:

• Confirm ascending aortic dimensions (48 mm by echo requires CT confirmation per guidelines) 1
• Evaluate aortic arch anatomy
• Assess coronary artery anatomy (BAV patients have higher incidence of coronary anomalies) 6
• Plan cannulation strategy

Risk Assessment

Calculate STS-PROM score for informed consent. At age 42 with no comorbidities and preserved EF, predicted operative mortality should be <2% for AVR + ascending aortic replacement at an experienced center.

Common Pitfalls to Avoid

1. Delaying surgery for "optimization": Symptomatic severe AS is a surgical emergency. Medical therapy does not improve outcomes and delays definitive treatment.

2. Replacing only the valve: Leaving a 48 mm ascending aorta in a BAV patient violates guidelines and necessitates future reoperation 1, 2, 3.

3. Considering TAVI: At age 42, surgical AVR is mandatory 5. TAVI is contraindicated in young patients requiring lifelong durability, and does not address the ascending aortic aneurysm 4.

4. Underestimating AR severity: The moderate AR may worsen acutely if the patient develops heart failure symptoms. Do not delay surgery to "watch" the AR.

Postoperative Surveillance

After successful AVR and ascending aortic replacement:

• Annual echocardiography: Monitor mechanical valve function, residual/recurrent AR, LV remodeling
• CT or MRI every 5 years: Surveillance of remaining native aorta (arch, descending thoracic aorta) for progressive dilation 1
• Warfarin management: Target INR 2.0-3.0, monthly monitoring once stable
• Endocarditis prophylaxis: Lifelong for mechanical valve

The dilated left atrium (not quantified) and mild mitral/tricuspid regurgitation should improve with afterload reduction post-AVR. The RVSP of 50 mmHg likely reflects elevated left-sided filling pressures from AS and should normalize.

Why Not Conservative Management?

Some might argue for watchful waiting given the patient's young age, but this is incorrect:

• Symptomatic severe AS has dismal natural history: 50% mortality at 2 years without intervention 2
• LV dysfunction may become irreversible: The concentric LVH will progress to decompensation if AS is not relieved
• Aortic complications: A 48 mm ascending aorta in BAV carries dissection risk, though lower than in Marfan syndrome 1, 2

Surgery now prevents premature death, improves quality of life, and addresses both the valve and aortic pathology in a single operation with excellent long-term outcomes 2, 9, 3.